Clinical Trial Update: Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cadonilimab with chemoradiation for recurrent and oligometastatic endometrial cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Endometrial Neoplasms, Neoplasm Recurrence, Local | Phase 2 | Status: RECRUITING